FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Peptide Reclassification 2026: What It Means for Providers BPC 157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven San Diego Orthobiologics Medical Group FDA Poised to Ease Restrictions on Injectable Peptides Af Pharmacy Purchasing & Products Magazine FDA to Convene Pharmacy Compounding Advisory Committee in July